Immucell Corp /De/ (ICCC) — 8-K Filings

8-K Filings (26)

• ImmuCell Corp Files 8-K on Dec 24 Events — Dec 29, 2025 Risk: medium
  ImmuCell Corporation filed an 8-K on December 29, 2025, reporting events that occurred on December 24, 2025. The filing indicates items related to material impa
• ImmuCell Corp Files 8-K on Financials — Nov 13, 2025 Risk: low
  ImmuCell Corporation filed an 8-K on November 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
• ImmuCell Corp Appoints New Directors, One Departs — Nov 4, 2025 Risk: low
  On October 29, 2025, ImmuCell Corporation reported the departure of Director Dr. Michael J. McGeary. The filing also noted the election of two new directors, Dr
• ImmuCell Corp Files 8-K on Financials — Oct 7, 2025 Risk: low
  ImmuCell Corporation filed an 8-K on October 7, 2025, reporting on its financial condition and results of operations. The filing does not contain specific finan
• ImmuCell Corp Files 8-K: Agreements, Personnel & Financials — Sep 30, 2025 Risk: medium
  On September 29, 2025, ImmuCell Corporation filed an 8-K report detailing several key events. These include the entry into a material definitive agreement, chan
• ImmuCell Corp Enters Material Definitive Agreement — Aug 25, 2025 Risk: medium
  On August 20, 2025, ImmuCell Corporation entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation
• ImmuCell Corp Files 8-K: Material Agreement & Financial Obligations — Aug 12, 2025 Risk: medium
  On August 7, 2025, ImmuCell Corporation entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation o
• ImmuCell Corp Files 8-K on Financials — Jul 9, 2025 Risk: low
  On July 9, 2025, ImmuCell Corporation filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, as well as
• ImmuCell Corp Files 8-K Report — Jun 25, 2025 Risk: low
  On June 25, 2025, ImmuCell Corporation filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating upd
• ImmuCell Corp Files 8-K on Shareholder Vote Matters — Jun 17, 2025 Risk: medium
  On June 12, 2025, ImmuCell Corporation filed an 8-K report detailing a submission of matters to a vote of its security holders. The filing does not specify the
• ImmuCell Corp Files 8-K on Operations and Financials — Apr 8, 2025 Risk: low
  On April 8, 2025, ImmuCell Corporation filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well a
• ImmuCell Corp Files 8-K: Material Agreement, Officer Changes — Apr 7, 2025 Risk: medium
  On April 4, 2025, ImmuCell Corporation entered into a material definitive agreement and reported changes in its board and officer compensation. The company also
• ImmuCell Corp Files 8-K on Financials — Feb 25, 2025 Risk: medium
  ImmuCell Corporation filed an 8-K on February 25, 2025, reporting on its financial condition and results of operations. The filing details the company's financi
• ImmuCell Corp Files 8-K Report — Jan 16, 2025 Risk: low
  On January 16, 2025, ImmuCell Corporation filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating
• ImmuCell Corp Files 8-K on Financials — Jan 10, 2025 Risk: low
  On January 9, 2025, ImmuCell Corporation filed an 8-K report detailing its financial results and operations. The filing provides information on the company's fi
• ImmuCell Corp Reports Material Agreements and Officer Changes — Dec 9, 2024 Risk: medium
  On December 6, 2024, ImmuCell Corporation entered into a material definitive agreement and simultaneously terminated a prior material definitive agreement. The
• ImmuCell Corp Files 8-K: Material Definitive Agreement — Dec 2, 2024 Risk: medium
  On November 29, 2024, ImmuCell Corporation entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement or any
• ImmuCell Corp Files 8-K on Financials — Oct 8, 2024 Risk: low
  ImmuCell Corporation filed an 8-K on October 8, 2024, to report on its results of operations and financial condition, as well as to file financial statements an
• ImmuCell Corp Files 8-K: Material Agreement & Financial Obligations — Sep 24, 2024 Risk: medium
  On September 20, 2024, ImmuCell Corporation entered into a material definitive agreement, likely related to financing or operations, as indicated by the filing
• ImmuCell Corp Files 8-K with Financial Updates — Jul 9, 2024 Risk: low
  On July 9, 2024, ImmuCell Corporation filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits
• ImmuCell Corp Files 8-K on Security Holder Vote — Jun 14, 2024 Risk: low
  On June 13, 2024, ImmuCell Corporation filed an 8-K report indicating a submission of matters to a vote of security holders. The filing does not contain specifi
• ImmuCell Corp Files 8-K Report — Jun 6, 2024 Risk: low
  On June 5, 2024, ImmuCell Corporation filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specifi
• ImmuCell Corp Files 8-K on Financials — Apr 9, 2024 Risk: low
  On April 9, 2024, ImmuCell Corporation filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits
• ImmuCell Corp Files Form 8-K — Mar 6, 2024 Risk: medium
  On March 4, 2024, ImmuCell Corporation entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices
• ImmuCell Reports Financial Condition on Feb 27, 2024 — Feb 27, 2024 Risk: low
  ImmuCell Corporation filed an 8-K on February 27, 2024, to report on its results of operations and financial condition. The filing indicates that the company, b
• ImmuCell Files 8-K on Operations & Financial Condition — Jan 8, 2024
  ImmuCell Corporation filed an 8-K on January 8, 2024, to report on its results of operations and financial condition. This filing, under SEC File Number 001-129

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX